List view / Grid view
19 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Out of 34 sites tested, 16 were found to be harbouring bacteria resistant to antibiotics, according to the report. Resistance to three major antibiotics...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Regeneron Pharmaceuticals and Sanofi’s two placebo-controlled Phase 3 trials, evaluating dupixent (dupilumab) in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), met their primary endpoints evaluating the extent and severity of the disease.
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The trial showed adding praluent to existing therapy reduced LDL cholesterol by approximately 50% from baseline, compared to 2% increase for placebo...
Currently, subcutaneous delivery of therapeutic proteins is a fast-growing field, especially for such established modalities as monoclonal antibodies, which require large quantities of drug to be administrated. Different approaches, including high protein concentration, speciality formulations and drug delivery matrices, as well as devices enabling a more rapid administration of larger…
15 August 2016 | By Sanofi
Results of the study affirm the vaccine's consistent efficacy in reducing dengue in two-thirds of the study participants, aged 9 and older. It also documents the ability of the vaccine to prevent 8 out of 10 hospitalisations and up to 93% of severe dengue cases in this age group during…
1 August 2016 | By Sanofi / Regeneron Pharmaceuticals, Inc.
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis...
28 July 2016 | By Sanofi
U.S. Food and Drug Administration (FDA) have approved Sanofi's Adlyxin TM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes...
6 July 2016 | By Victoria White, Digital Content Producer
Medivation has entered into confidentiality agreements with parties that have expressed interest in exploring a potential transaction to acquire the company...
27 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Boehringer Ingelheim have signed contracts to secure the exchange of Sanofi's Merial and Boehringer Ingelheim's consumer healthcare business...
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
Results from Sanofi’s Phase III LixiLan-O and LixiLan-L clinical trials have been presented at the American Diabetes Association 76th Scientific Sessions.
6 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Regeneron have announced that a one-year Phase III study evaluating investigational dupilumab met its primary and key secondary endpoints.
31 May 2016 | By Victoria White, Digital Content Producer
Reputation Institute has announced that AbbVie, Sanofi and Novo Nordisk top the RepTrak ranking of the most reputable pharmaceutical companies in the UK...
26 May 2016 | By Victoria White, Digital Content Producer
The FDA's EMDAC has recommended the approval of the NDA for the fixed-ratio combination of insulin glargine and lixisenatide...
25 May 2016 | By Victoria White, Digital Content Producer
Sanofi says it had 'no choice' but to commence a process to elect eight independent directors who are more open to evaluating Sanofi's takeover proposal...
